Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099151 | 0.83 | ESR1 (0.41) | ESR1ESR2ARPDE2A | |
| SCHEMBL29446073 | 0.80 | ADRB2 (0.34) | KDM1ARCOR1PDE2ATDP1CYP1A2 | |
| SCHEMBL22964477 | 0.80 | ADRB2 (0.34) | KDM1ARCOR1PDE2ATDP1CYP1A2 | |
| SCHEMBL24331301 | 0.79 | MAPT (0.39) | ESR1ESR2ARKMT2ANPSR1 | |
| SCHEMBL12982333 | 0.79 | CNR2 (0.42) | ESR1ESR2 | |
| SCHEMBL4153765 | 0.77 | ALOX15 (0.46) | ESR1ESR2KDM1ARCOR1AR | |
| SCHEMBL1104683 | 0.77 | ALDH1A1 (0.41) | KDM1ARCOR1KMT2ATDP1CYP1A2 | |
| SCHEMBL20866516 | 0.76 | RIPK1 (0.39) | ESR1ESR2ARPDE2A | |
| SCHEMBL16046268 | 0.75 | KDM1A (0.36) | KDM1ARCOR1PDE2ATDP1KCNH2 | |
| SCHEMBL22021978 | 0.75 | TRPV4 (0.43) | ESR1ESR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | ESR1 4021/4885ESR2 2458/4885KDM1A 2929/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | ESR1 4021/4885ESR2 2458/4885KDM1A 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.